View Older Stories View More Recent Stories
-
Syneos Health (SYNH) Acquired by Investment Consortium for $43/sh or $7.1B Cash
-
Syneos Health to be Acquired by a Private Investment Consortium for Approximately $7.1 Billion
-
Wheaton Precious Metals Corp. (WPM) Renews At-The-Market Equity Program
-
Wheaton Precious Metals Announces Renewal Of Its At-The-Market Equity Program
-
Under Armour expects dull annual sales, profit as demand slows
-
Nickel 28 Rejects Pelham’s Latest Zero Premium Take-Over Attempt
-
BMO Capital Downgrades Skyworks Solutions (SWKS) to Market Perform, 'More Questions Than Answers'
-
Bunge to Participate at BMO Capital Markets Global Farm to Market Conference in New York City
-
The Special Committee of the Board of Directors of Liminal Biosciences Retains an Independent Financial Advisor in Response to Unsolicited Non-Binding Transaction Proposal
-
Peloton (PTON) upgraded at BMO as risk/reward appears "skewed upward at current levels"
-
BMO Capital Upgrades Peloton Interactive (PTON) to Market Perform
-
Morphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Nickel 28 Acknowledges Receipt of Director Nomination Notice
-
Analysts adjust Qorvo (QRVO) price targets following Q4 top and bottom line beat
-
Wall Street analysts positive on SolarEdge Technologies (SEDG) following earnings beat
-
Wall Street analysts lift Verisk Analytics (VRSK) following earnings, revenue beat
-
US jobs market softening; slumping productivity boosts labor costs
-
Peloton shares nosedive after wider loss, dour membership forecast
-
Arconic (ARNC) agrees to be acquired by Apollo for $30/share
-
Arconic to Be Acquired by Apollo Funds
-
Regeneron's Eylea drug sales hit by competition from 'new kid in town'
-
Novo Nordisk rivals see room to compete in $100 billion weight-loss drug market
-
Immunogen (IMGN) surges on 'home run' ovarian cancer treatment trial data
-
Livent Corporation (LTHM) jumps after lifting 2023 revenue forecast
-
Immunogen Inc. (IMGN) Elahere Data 'Simply Mirvelous!' - BMO
-
Morphic Therapeutic (MORF) Announces Proposed Public Offering
-
Morphic Therapeutic Announces Proposed Public Offering
-
Atalaya Mining PLC Announces Notice of Q1 2023 Results
-
ADM to Present at 2023 BMO Capital Markets Global Farm to Market Conference
-
Above Food Corp to Go Public via Merger with Bite Acquisition (BITE)
-
Above Food Corp., a Vertically Integrated Specialty Ingredients and Food Company, to List on NYSE Through Business Combination with Bite Acquisition Corp.
-
Enbridge (ENB) to Acquire Aitken Creek Natural Gas Storage from FortisBC Holdings Inc. for $400M
-
Enbridge to Acquire Aitken Creek Natural Gas Storage from FortisBC Holdings Inc. for $400 million
-
Canada's economy slowed in February, backing up pause on rates
-
Checkpoint Software (CHKP) PT Lowered to $140 at BMO Capital on 'increased concerns'
-
Orchid Island Capital Announces First Quarter 2023 Results
-
Amgen 1st quarter profit falls as costs rise, sales up 2%
-
Drugmakers scout for deals, ramp up research spending
-
Ninepoint Enhances Private Credit Fund With BMO Credit Facility
-
BMO Capital cuts Electronic Arts (EA) to Market Perform over 'lingering concerns'
-
At $50M, Anthemis' Female Innovators Lab Fund Becomes the Largest Early-stage Fintech Fund Dedicated to Companies Founded by Women
-
AbbVie posts weak sales of newer drugs as Humira faces fresh competition, shares fall
-
BMO Capital Downgrades Progressive Corp. (PGR) to Market Perform, 'Near-Term Estimates Likely to Continue Resetting'
-
BMO Capital Downgrades Electronic Arts (EA) to Market Perform
-
Abaxx Provides Corporate Update, Appoints Abaxx Singapore Directors and Establishes At-The-Market Equity Program
-
'This is a shocking development' - BMO Capital on UK blocking Microsoft's (MSFT) takeover of Activision Blizzard (ATVI)
-
Bank of Canada rate-cut bets recede as core inflation proves sticky
-
BMO Capital Upgrades Microsoft (MSFT) to Outperform, 'Returning to Positive View With Focus on Longer-Term AI'
-
Harley-Davidson (HOG) fears are overdone - BMO
-
Morphic Therapeutic (MORF) PT Raised to $106 at BMO Capital

